Hostname: page-component-6766d58669-fx4k7 Total loading time: 0 Render date: 2026-05-17T13:21:34.440Z Has data issue: false hasContentIssue false
  • English
  • Français

Epistaxis in patients taking oral anticoagulant and antiplatelet medication: prospective cohort study

Published online by Cambridge University Press:  16 September 2010

J Smith ,
S Siddiq ,
C Dyer ,
J Rainsbury  and
D Kim
J Smith*
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, University Hospital Birmingham, UK
S Siddiq
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, University Hospital Birmingham, UK
C Dyer
Affiliation:
Department of Otolaryngology, Worcester Royal Hospital, UK
J Rainsbury
Affiliation:
Department of Otolaryngology, Worcester Royal Hospital, UK
D Kim
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, University Hospital Birmingham, UK
*
Address for correspondence: Mr J Smith, 27 Northlands Road, Moseley, Birmingham B13 9RE, UK Fax: +44 (0)121 6978406 E-mail: joelsmith999@hotmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

Epistaxis can be caused or exacerbated by anticoagulant and antiplatelet therapy. This prospective study assessed the prevalence of epistaxis in patients taking anticoagulant and antiplatelet medication, and monitored differences in patients’ clinical courses.

Method:

Prospective data were collected for consecutive patients referred with epistaxis from the emergency department over a seven-month period. Emergency department records were used to investigate prevalence and referral rates.

Results:

Over the study period, 290 patients presented to the emergency department with epistaxis; this represented 0.9 per cent of all emergency attendances. Of these patients, 119 (39 per cent) were referred on to the ENT department, 62 per cent of whom were currently taking anticoagulant or antiplatelet medication. Patients taking anticoagulant and antiplatelet medication were a significantly older group (relative risk 1.50 (1.08–2.28), p = 0.01) requiring longer in-patient stays (relative risk 2.50 (1.01–4.97), p = 0.01) and more aggressive local haemostasis measures. Most patients taking warfarin had an international normalised ratio outside the appropriate range for their disease. Hypertension was not a factor in these patients’ clinical course.

Conclusion:

Increasingly, emergency and ENT departments are being presented with epistaxis in patients taking anticoagulant or antiplatelet medication. A better understanding of such medication and its effects may enable more effective management of these patients.

Keywords

EpistaxisAnticoagulantsAntiplateletsPrevalenceComplicationsClinical Course

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 125 , Issue 1 , January 2011 , pp. 38 - 42
Copyright
Copyright © JLO (1984) Limited 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1 Elahi, MM, Parnes, LS, Fox, AJ, Pelz, DM, Lee, DH. Therapeutic embolisation in the treatment of intractable epistaxis. Arch Otolaryngol Head Neck Surg 1995;121:65–9Google Scholar
2 Pope, LER, Hobbs, CGL. Epistaxis: an update on current management. Postgrad Med J 2005;81:309–14Google Scholar
3 Vedovati, MC, Becattini, C, Agnelli, G. Combined oral anticoagulants and antiplatelets: benefits and risks. Intern Emerg Med 2010;5:281–90CrossRefGoogle ScholarPubMed
4 Hollowell, J, Ruigómez, A, Johansson, S, Wallander, MA, García-Rodríguez, LA. The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom. Brit J Gen Pract 2003;53:312–14Google Scholar
5 The management of atrial fibrillation. In: http://guidance.nice.org.uk/CG36 [5 January 2010]Google Scholar
6 Varshney, S, Saxena, RK. Epistaxis: A retrospective clinical study. Indian J Otolaryngol Head Neck Surg 2005;57:125–9CrossRefGoogle ScholarPubMed
7 Wormald, PJ. Update on epistaxis. Curr Opin Otolaryngol Head Neck Surg 2007;15:180–3Google Scholar
8 Viducich, RA, Blanda, MP, Gerson, LW. Posterior epistaxis: clinical features and acute complications. Ann Emerg Med 1995;25:592–6Google Scholar
9 Barlow, DW, Deleyiannis, FWB, Princzower, EF. Effectiveness of surgical management of epistaxis at a tertiary care centre. Laryngoscope 1997;107:21–4Google Scholar
10 Frikart, L, Agrifoglio, A. Endoscopic treatment of posterior epistaxis. Rhinology 1998;36:59–61Google ScholarPubMed
11 Mendez-Jandula, B, Souto, JC, Oliver, A, Monserrat, I. Comparing self-management of oral anticoagulant therapy with clinical management: a randomised trial. Ann Int Med 2005;142:1–10Google Scholar
12 Hylek, EM, Evans-Molina, C, Shea, C, Henault, LE, Regan, S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689–96Google Scholar
13 Hylek, EM, Chang, YC, Skates, SJ, Hughes, RA, Singer, DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160:1612–17Google Scholar
14 Srinivasen, V, Patel, H, John, DG, Worsley, A. Warfarin and epistaxis: should warfarin always be discontinued? Clin Otolaryngol Allied Sci 1997;22:542–4Google Scholar